Cargando…
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
Obesity and obesity related kidney and liver disease have become more prevalent over the past few decades, especially in the western world. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic agents with promising effects on cardiovascular and renal function. Given SGLT...
Autores principales: | Wang, Dong, Luo, Yuhuan, Wang, Xiaoxin, Orlicky, David J., Myakala, Komuraiah, Yang, Pengyuan, Levi, Moshe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796086/ https://www.ncbi.nlm.nih.gov/pubmed/29301371 http://dx.doi.org/10.3390/ijms19010137 |
Ejemplares similares
-
Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
por: Wang, Dong, et al.
Publicado: (2017) -
SRGAP2a: A New Player That Modulates Podocyte Cytoskeleton and Injury in Diabetes
por: Levi, Moshe, et al.
Publicado: (2018) -
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009) -
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020) -
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice
por: Han, Tuo, et al.
Publicado: (2021)